Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical has shown significant fluctuations in its financial performance and trading activities, with a notable decrease in revenue and net profit in the recent reporting period [1][2]. Group 2 - On November 11, Duorui Pharmaceutical's stock price increased by 0.02%, with a trading volume of 89.78 million yuan. The financing buy-in amount for the day was 12.24 million yuan, while the financing repayment was 11.49 million yuan, resulting in a net financing buy-in of 0.75 million yuan [1]. - As of November 11, the total financing and securities lending balance for Duorui Pharmaceutical was 190 million yuan, which accounts for 4.20% of its circulating market value, indicating a high level of financing compared to the past year [1]. - The company has not engaged in any securities lending activities on November 11, with both the securities lending repayment and selling amount recorded as zero [1]. - Duorui Pharmaceutical, established on December 22, 2016, and listed on September 29, 2021, focuses on the research, production, and sales of chemical drug formulations and their raw materials. The revenue composition is as follows: formulations 37.60%, intermediates 35.78%, raw materials 21.64%, and others 4.98% [1]. Group 3 - As of September 30, the number of shareholders for Duorui Pharmaceutical was 6,361, a decrease of 16.60% from the previous period. The average circulating shares per person increased by 19.90% to 12,576 shares [2]. - For the period from January to September 2025, Duorui Pharmaceutical reported a revenue of 137 million yuan, a year-on-year decrease of 31.68%. The net profit attributable to the parent company was -79.73 million yuan, reflecting a significant year-on-year decline of 366.82% [2]. - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2].
多瑞医药11月11日获融资买入1224.45万元，融资余额1.90亿元